• SOLUTION SETS
  • NEWSLETTERS
  • LOGIN
  • Follow us on   Upload your Case Studies  
    JOIN CONTENTREE
SIGN UP
Home

Case Study

KYM001, first in class oral IRAK4 protein degraders Case Study

KYM001, first in class oral IRAK4 protein degraders Case Study

KYM001, first in class oral IRAK4 protein degraders Case Study

Kymera
Pages 1 Pages

Recurrent mutations in MYD88 drive 30 40% of ABC-DLBCL; MYD88 L265P is the most prevalent. IRAK4 is a critical component of the Myddosome.

Join for free to read

You Might Also Like


A First-in-Class Selective and Potent IRAK4 Degrader Case Study
Case Study A First-in-Class Selective and Potent IRAK4 Degrader Case Study
Kymera

Targeted protein degradation in oncology and beyond Case study
Case Study Targeted protein degradation in oncology and beyond Case study
Kymera

Targeted Protein Degradation Beyond Oncology Case Study
Case Study Targeted Protein Degradation Beyond Oncology Case Study
Kymera

2953 Targeted Degradation of IRAK4 Protein Via Heterobifunctional Small Molecules for Treatment of MYD88 Mutant Lymphoma Case Study
Case Study 2953 Targeted Degradation of IRAK4 Protein Via…
Kymera

More from Kymera


A First-in-Class Selective and Potent IRAK4 Degrader Case Study
Case Study A First-in-Class Selective and Potent IRAK4 Degrader Case Study
Kymera

Targeted protein degradation in oncology and beyond Case study
Case Study Targeted protein degradation in oncology and beyond Case study
Kymera

Targeted Protein Degradation Beyond Oncology Case Study
Case Study Targeted Protein Degradation Beyond Oncology Case Study
Kymera

2953 Targeted Degradation of IRAK4 Protein Via Heterobifunctional Small Molecules for Treatment of MYD88 Mutant Lymphoma Case Study
Case Study 2953 Targeted Degradation of IRAK4 Protein Via…
Kymera
B2B solutions from all vendors in all industries aggregated and curated in an easy-to-use discovery platform
Follow us on  
Upload your Assets  
JOIN CONTENTREE
  • Blogs
  • Vendor Centers
  • Solution Sets
  • About us
  • Contact us
© 2025 Contentree.  All Rights Reserved   |   Privacy and Cookies   |   Legal   |   Do not sell my info